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for SEC and UST were 6.84, 2.87, € 54,428 and 6.79, 2.08, € 54,572, respectively. 
Probabilistic sensitivity analysis indicated robustness in the Conclusionsof domi-
nance/highly cost-effective approach for SEC vs. UST. ConClusions: Applying 
stricter criteria for response (i.e., PASI≥ 75 instead of PASI≥ 50) for treatment dis/
continuation for highly efficacious PSO therapy (SEC) Resultsin overall greater 
QALYs and cost savings for the health-care system.
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objeCtives: There are limited data on healthcare resource utilisation associated 
with inadequately controlled chronic spontaneous (idiopathic) urticaria (CSU/
CIU) patients. ASSURE-CSU is an observational, multinational study conducted to 
identify and quantify burden of illness in these patients. Data on resource utilisa-
tion for Canada, Germany, UK and the Netherlands are summarised. Methods: 
This study included a 1-year retrospective medical record abstraction and a cross-
sectional patient-reported outcomes survey. Adult CSU/CIU patients with disease 
persisting for ≥ 12 months despite treatment were assessed. Data on resource 
utilisation were extracted from patient medical records, and reported descrip-
tively. Results: Medical records were abstracted for 99 patients each in Canada 
and the Netherlands, 100 in Germany and 83 in the UK. In Canada, 83% patients 
had one or more visits to a health care professional (HCP) with a total mean (SD) 
of 3.1 (2.57) annual visits. In the prior 12 months, visits to allergists and derma-
tologists were reported by 72% and 11% patients. In Germany, 52% patients visited 
HCPs [annual visits: 3.3 (3.81)]. Hospitalisations and emergency room (ER) visits 
were reported by 18% and 15% patients. Allergists and dermatologists were visited 
by 33% and 31% patients. In UK, 86% patients visited HCPs [annual visits: 3.7 (2.68)]. 
Dermatologists were seen by 54% patients, allergists by 30% and hospital nurses 
by 10%. HCPs were visited by 87% patients in the Netherlands [annual visits: 4.1 
(3.87)]. Visits to dermatologists, allergists and other consultants were reported by 
51%, 42% and 13% patients. ER visits and hospitalisations were less frequent in 
Canada, the UK and the Netherlands compared with Germany. ConClusions: 
This is the first study to quantify resource utilisation associated with inadequately 
controlled CSU/CIU. The types of medical resources differ among the countries 
depending on the local healthcare specificities. Resource utilisation pattern was 
primarily outpatient but varied across countries.
SenSory SyStemS diSorderS – Patient-reported outcomes & Patient  
Preference Studies
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objeCtives: Chronic urticaria (CU) (or chronic hives) can be inducible or spontane-
ous (also known as idiopathic urticaria) (CSU/CIU). Data supporting the impact of 
CSU/CIU on patients and comparison with other dermatological diseases are scarce. 
This study evaluated economic burden associated with CU relative to psoriasis (PsO) 
overall and different severity levels of PsO among the adults in 5 European (France, 
Germany, Italy, Spain and UK) countries. Methods: Data from patients diagnosed 
with chronic hives (proxy for CSU) and PsO were collected in the National Health 
and Wellness Survey (NHWS). Outcome measures included the Work Productivity 
and Activity Impairment (WPAI) questionnaire and self-reported healthcare use in 
prior 6 months. Generalized linear models with different link functions were used 
to compare patients with CU vs. overall PsO (includes all severity levels) and CU 
vs. moderate-severe-PsO, controlling for patient characteristics. Results: Study 
included 769 CU patients and 7,857 PsO patients (26.9% moderate-severe). CU 
patients reported non-significant higher rate ratio (RR) of absenteeism (RR= 1.31), 
presenteeism (1.15) and overall work impairment (1.15) than overall PsO, however, 
activity impairment was significantly higher among CU patients (1.21; p< 0.05). 
The rates of work and activity impairment were similar between CU and moder-
ate-severe-PsO patients (RR: absenteeism; 0.99, presenteeism; 0.97, overall work 
impairment; 0.97 and activity impairment; 1.08) (all p= NS). Rate of healthcare vis-
its were higher among CU than overall PsO (RR: HCP visits; 1.16, ER visits; 2.13, 
Hospitalizations; 1.94, all p< 0.001) and also than moderate-severe-PsO patients (RR: 
HCP visits;1.07, ER visits;1.77, Hospitalizations;1.47, all p< 0.001). ConClusions: 
Patients with CU and PsO report a similar negative impact on work ability. Compared 
to overall PsO patients with CU have a significantly higher impact on daily activities 
and non-significant higher impairment on work components. The impact on work 
and activities is similar among CU and moderate-severe PsO. CU patients report 
significantly higher use of medical resources than Pso.
objeCtives: To estimate the incremental cost-utility ratio (ICUR) for ingenol mebu-
tate vs diclofenac 3% for actinic keratosis (AK) patient’s treatment on the face and 
scalp, and trunk and extremities, in Spain. Methods: A hypothetical cohort of 73 
aged AK patients was simulated for a 5-year time horizon with a Markov model. 
Duration of treatments was 3 days (face-scalp) and 2 days (trunk-extremities) for 
ingenol mebutate and 90 days (face-scalp and trunk-extremities) for diclofenac. 
Total clearances rates (42.24% and 34.07% for ingenol mebutate and 24.64% and 
25.07% for diclofenac on face-scalp and on trunk-extremities, respectively) obtained 
from indirect mixed comparisons and adjusted according compliance were used 
as effectiveness measure. Annual recurrence rate (20%) derived from literature. 
The perspective of the Spanish National Health System (NHS) was choosen. Total 
cost estimation (€ ,2015) included: pharmaceutical cost (retail price VAT included 
with mandatory deduction), and dermatology visits cost (for adverse events and 
disease management).A 3% annual discount rate was applied for costs and out-
comes. Utilities values (0.986 for AK and 1.00 for clearance) were used to derive 
quality-adjusted-life years (QALY). Several sensitivity analyses were performed to 
test model robustness. Results: Ingenol mebutate showed higher effectiveness, 
with 0.192 incremental clearances and 0.011 incremental QALYs (face-scalp), and 
0.129 incremental clearances and 0.007 incremental QALYs (trunk-extremities) 
compared to diclofenac. Total costs accounted were € 551.50 and € 622.27 (46% drug 
cost) for ingenol mebutate, compared to € 849.11 and € 844.93 (54% drug cost) for 
diclofenac (for face-scalp and trunk-extremities, respectively). Ingenol mebutate 
versus diclofenac 3% was dominant on face-scalp and trunk-extremities AK treat-
ment. Further, ingenol mebutate remained a dominant option in 96% (face-scalp) 
and 91% (trunk-extremities) of the 1,000 MonteCarlo simulations of probabilistic 
sensitivity analysis. ConClusions: Ingenol mebutate was a dominant strategy for 
Spanish NHS, compared to diclofenac 3%, for treatment of patients with AK both, 
face-scalp and trunk-extremities.
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objeCtives: Secukinumab (SEC300), an IL-17A antibody, was recently approved as 
highly effective therapy for moderate-to-severe plaque psoriasis (PSO). We examined 
the cost-effectiveness of SEC300 compared against other systemic biologic drugs: 
adalimumab (ADA), etanercept (ETA), infliximab (INF), ustekinumab (UST) 45 and 
90 mg, and standard of care (SOC - cyclosporine and methotrexate) for plaque pso-
riasis, in the Italian National Health System (NHS) setting. Methods: A previous 
cost-effectiveness model was adapted to the Italian healthcare setting. The model 
was designed to consider the clinical benefits, resource use and costs related to 
SEC300. A decision tree reflecting response to treatment (PASI change < 50, 50-75, 
75-90, 90-99, 100) fed into a long-term Markov model with health states related 
to treatment continuation, dropout, and death. Clinical data (PASI change scores, 
percentage of adverse events, discontinuation rate) and utility scores were derived 
from clinical trials as well as from published evidence on Italian patients. The per-
spective of the model is the Italian NHS, therefore only direct medical costs (drug 
prices, inpatient and outpatient hospital tariffs, etc.) were taken in account. Both 
costs and benefits were discounted at 3% according to Italian National Guidelines 
for Health Economics Evaluations. Incremental cost-effectiveness ratios (ICERs) 
were calculated. Results: At 10 years, SEC300 is a dominant (less costly and more 
effective) option compared with UST45 and UST90. It is a cost-effective option – with 
a threshold < € 50,000/QALY gained as per National Health Economics Evaluation 
Guidelines – vs. ADA, IFN, ETA, and SOC with an ICERs of € 37,252, € 48,949, € 21,943 
and € 41,896, respectively. The sensitivity analysis demonstrated the robustness of 
model results. ConClusions: The model shows that SEC300 is a cost‐effective 
option when compared to other biologic agents and SOC currently funded by NHS 
in Italy for the treatment of moderate-to-severe plaque psoriasis.
PSS51
coSt-eFFectiveneSS analySiS oF SecukinumaB comPared to 
uStekinumaB in tHe treatment oF moderate to Severe Plaque 
PSoriaSiS in tHe czecH rePuBlic
Klimes J1, Mollon P2, Graham C3, Rajnoch J1, Dostal F1, Skalicky D1, Jordan P1, Depta J2
1Novartis, s.r.o., Prague, Czech Republic, 2Novartis Pharma AG, Basel, Switzerland, 3RTI Health 
Solutions, NC, NC, USA
objeCtives: Secukinumab (SEC), an IL-17A antibody, is a new highly effective 
therapy for moderate-to-severe plaque psoriasis (PSO). Ustekinumab (UST) is 
reimbursed in the Czech Republic under the condition of ≥ PASI50 response at 
week 16. We estimated the cost effectiveness of SEC vs. UST based on differ-
ent PASI response (dis/continuation) criteria; PASI≥ 75 for SEC and PASI≥ 50 for 
UST. Methods: A decision tree reflecting response to treatment (PASI change 
< 50, 50-75, 75-90, 90-99, 100) fed into a long-term Markov model with health states 
related to treatment continuation, dropout, and death. Responders at week 16 
(defined as PASI≥ 75 for SEC, PASI≥ 50 for UST) continued on biologic treatment. 
Non-responders and drop-outs were switched to standard-of-care (MTX, CyA, 
emollients). A health-care system perspective with 3% discount rate was adopted. 
Dosing schedule for maintenance treatment for SEC and UST as 12.0 and 4.35 
doses per year was calculated. Baseline patient characteristics and efficacy data 
were derived from the CLEAR study, a head-to-head 52-week superiority trial (SEC 
300 mg vs. UST 45/90 mg). Long-term treatment resistance and dropout were 
modelled by assuming a 20% annual discontinuation rate. Utility weights for each 
health state were calculated from EQ-5D measures from the SEC clinical pro-
gram. Results: With a 10-year time horizon, SEC treatment gains 0.05 QALYs and 
0.80 years in PASI≥ 90 with € 144 in cost savings vs. UST, reflecting dominance of 
SEC vs. UST. Absolute (discounted) QALYs, years in ≥ PASI90 and costs (discounted) 
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objeCtives: Treatment options continue to emerge for managing psoriasis, with 
different risk:benefit profiles and routes of administration. This study was designed 
to elicit UK patients’ relative strength of preference regarding treatment effectiveness, 
risks of side effects, and mode/frequency of administration. Methods: A stated 
preference survey (using a discrete choice experiment [DCE]) was designed to present 
participants with hypothetical treatment choices. Treatments were described in terms 
of reducing the body surface area (BSA) affected by psoriasis, mode of administration, 
increase in risk of diarrhea or nausea in the short-term, and 10-year risk of melanoma, 
tuberculosis, or serious infection (e.g., pneumonia). Standard DCE Methodswith an 
orthogonal design were used; the survey was pilot-tested in 6 participants. Results: 
Psoriasis patients (n= 292; mean age= 48.5 years; mean BSA= 9.3%; mean Dermatology 
Life Quality Index= 10.5; 25.7% with prior biologic experience and 34.9% with pso-
riatic arthritis) were recruited in the UK. Participants strongly preferred to avoid 
increasing their risk of melanoma (odds ratio [OR]= 0.44/5% increased 10-year risk), 
tuberculosis, and serious infections (OR= 0.73/5% increased 10-year risk for both) 
and preferred twice-daily tablets to weekly injections (OR= 0.74) or injections every 
2 weeks (OR= 0.86). Participants preferred to avoid treatments with a risk of diarrhea 
or nausea in the first few weeks after initiation (OR= 0.87/5% increase) and preferred 
treatments that effectively resolve plaque lesions (OR= 0.93 for each hand palm area 
still affected). All ORs were statistically significant. Biologic-naïve participants were 
more likely to prefer oral tablets to injections and were less risk-tolerant for serious 
adverse events. ConClusions: All attributes of treatment considered were found 
to be significant predictors of choice. Patients showed strong preferences for avoiding 
treatments with risk of serious toxicities and avoiding injectable therapy, and a lower 
preference for treatments with greater efficacy. These preferences were consistently 
stronger in biologic-naïve patients.
PSS57
aSSeSSment oF dental StatuS and PercePtion towardS oral HealtH 
among PHarmacy StudentS in quetta, PakiStan
ul Haq N, Ejaz M, Iqbal Q, Nasim A, Riaz S, Haque N, Akram A
University of Balochistan, Quetta, Pakistan
objeCtives: This study is design to assess the dental status and perception towards oral 
health among pharmacy students. Methods: The study is questionnaire bases cross 
sectional study. Study is conducted in Faculty of Pharmacy, University of Balochistan, 
Quetta by using convenient sampling. The descriptive statistics was used to present 
the demographic and disease related information. Inferential statistics was used to the 
evaluation relationship among study variables. All analyses were performed using SPSS 
20.0. Results: Out of 197 participants 196 (66.0%) were male. Majority of participants 
267 (89.9%) having age ranges between 18-24 years. One hundred ninety one (64.3%) 
describe that they have no problem in chewing and 172 (53.9%) are satisfied with their 
teeth appearance which shows the satisfaction of participants concerning their oral 
dental health. Majority of respondents 120 (40.4%) were satisfied with their teeth. One 
hundred and sixty one (54.2%) respondents were having minor teeth problems. Score for 
self-rating of dental health in majority of participants 121 (40.7%) was excellent. When 
discussing the self-rating score no significance difference was found in participants 
having dental problem, broken filling, broken tooth, cavities, bleeding gums, bad breath, 
stained teeth, aches and broken denture. ConClusions: Present Study concluded that 
although the participant were satisfied with their oral dental health, yet they are not 
aware about the proper hygiene and oral dental health. Awareness program must be 
initiated for students, focusing primarily on dental/oral health.
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objeCtives: Acne vulgaris is one of the most common skin conditions, affecting 
primarily the adolescents. The psychological impact associated with the condition 
could be explained by the predominance of lesions in the face. The objective of the 
present study was to describe the characteristics of the disease and its management 
in Europe considering the patients’ perspective. Methods: A cross-sectional survey 
was conducted in a sample of individuals residing in Europe and aged 15 to 24. To 
ensure representativeness, the quota method was applied considering age, sex, resi-
dence location and occupational status of the reference person. Study participants 
were asked to complete an online questionnaire specifically developed for the study 
and Resultswere analysed descriptively. Results: A total of 3099 study participants 
declared currently having acne. Outside of the face, the back was affected by lesions 
in 61.05% of individuals on average (65.95% of men and 56.22% of women). Most 
patients (27.03%) reported their general physician or dermatologist as the main source 
of information on acne. However, advices were also often sought from relatives and 
internet. In addition, whereas the diagnosis of acne is generally made by a derma-
tologist (29.69%), most patients, reporting acne in our study, declared that no medical 
diagnosis was ever made (39.3%). This can explain why most individuals (28.65%) 
reported using anti-acne cosmetics advised by their pharmacists instead of prescribed 
treatments. Finally, according to patients’ perspective, acne is generally considered a 
minor issue however, for 21.3% of individuals it represents a major problem and 1.9% 
lives it as a real burden. These Resultsare consistent across the selected European 
countries. ConClusions: Acne is a common disease considered a minor issue by 
most adolescent patients and commonly self-managed using anti-acne cosmetics. 
However, patients often sought information and advices from healthcare profession-
als such as general practitioners, dermatologists or pharmacists.
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objeCtives: Although chronic spontaneous (idiopathic) urticaria (CSU/CIU) is not 
life threatening, it can significantly impact a patient’s life when not adequately 
controlled by medication. Patients experience disturbing itch, intermittent pain, lack 
of sleep, occupational disabilities and social isolation with high impact on health-
related quality of life (HRQoL). However, data on the humanistic burden associated 
with symptomatic persistent CSU/CIU is scarce. Here we present data on utility 
values from the first international burden of illness study in CSU/CIU. Methods: 
ASSURE-CSU is an observational, non-interventional study which included a 1-year 
retrospective medical record abstraction and a cross-sectional patient-reported out-
comes survey. Adult CSU/CIU patients aged > 18 years with disease persisting for ≥ 12 
months despite treatment were assessed. Utility values and domain scores from 
EQ-5D-3L were described for Canada, Germany, UK and the Netherlands. Results: 
A total of 88, 98, 79 and 99 patients completed the patient survey which included 
the EQ-5D-3L in Canada, Germany, UK and the Netherlands, respectively. The mean 
(SD) EQ-5D-3L utility score was 0.71 (0.30) for Canada; 0.71 (0.25) for Germany; 0.72 
(0.31) for UK and 0.76 (0.27) for the Netherlands. Among the different dimensions 
of EQ-5D-3L, pain/discomfort was the most affected with 62.0%, 70.5%, 61.5% and 
56.6% of patients reporting moderate to extreme problems, respectively. The second 
most affected dimension was anxiety/depression for Canada, Germany and UK with 
41.8%, 51.6% and 45.6% of patients reporting moderate to extreme problems, respec-
tively. For the Netherlands, usual activities (44.4%) was the second most affected 
dimension. Impact across all dimensions increased with disease severity and cor-
respondingly utility values decreased. ConClusions: This is the first real-world 
study to assess utility values in CSU/CIU using EQ-5D. Utility scores were similar 
among the countries and ranged from 0.71 to 0.76, suggesting that CSU/CIU have 
significant impact on the patients’ health status. Pain/discomfort was the most 
affected dimension across countries.
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objeCtives: To evaluate disease burden, clinical and patient-reported outcomes 
and healthcare costs of patients admitted to hospital for management of plaque 
or erythrodermic psoriasis. Methods: This observational study enrolled 61 eligible 
patients from 107 hospital stays across 9 UK hospitals. Sites recorded Psoriasis Area 
Severity Index (PASI) at admission and discharge, psoriasis treatments, and length 
of stay (LOS). Patients reported psoriasis-related symptoms, health status (SF-12v2, 
EQ-5D-3L), mood (HADS), productivity (WPAI), and dermatology-related quality of life 
(DLQI) at admission, and also reported psoriasis-related symptoms, EQ-5D-3L, and 
DLQI at discharge. An algorithm assigned cost/hospital stay. Descriptive statistics 
are based on those responding to each item. Statistical significance evaluated at the 
0.05 level. Results: Mean age was 45.5 years; 50.8% were male. Mean time since 
psoriasis diagnosis was 20.0 years. Most (78.7%) had ≥ 1 previous psoriasis-related 
hospitalization. Mean number of physician-diagnosed co-morbid conditions was 2.5. 
At admission, mean SF-12v2 Physical and Mental component summary scores were 
35.4 and 32.1, respectively; mean HADS scores were 9.7 (anxiety) and 9.6 (depres-
sion) indicating substantial impairment. Forty-five percent reported changing job, 
role, or position at work due to psoriasis. Mean WPAI activity impairment at admis-
sion was 68.7%; among the 35.1% employed for pay, mean WPAI work impairment 
was 79.2%. Mean PASI improved from admission to discharge (25.2→ 12.1; p< 0.0001). 
Also, improvement was seen at discharge for EQ-5D-3L (0.34 → 0.60), DLQI total score 
(20.1→ 12.0), and psoriasis symptom scores (all p< 0.05). Mean (range) LOS was 17.0 
(2,71) days; for 8 patients achieving a 75% reduction in PASI (PASI75), mean LOS was 
18.1 vs. 13.1 days for 27 patients not achieving PASI75 (p= 0. 11). Mean (SD) cost/hos-
pital stay was £4,875 (±£3,096). ConClusions: Disease burden, LOS and cost are 
substantial among patients hospitalized for psoriasis. On average, patients improved 
during their hospital stay. Nonetheless, they reported suboptimal clinical and patient-
reported outcomes at discharge.
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